SYNTHESIS OF ANTITUMOR/VIRAL PYRIMIDINE C NUCLEOSIDES
抗肿瘤/病毒嘧啶C核苷的合成
基本信息
- 批准号:3171656
- 负责人:
- 金额:$ 16.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1983
- 资助国家:美国
- 起止时间:1983-07-01 至 1990-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Chemical methods will be developed for the preparation of six classes of
C-nucleoside derivatives which are close analogs of either synthetic
derivatives with established antitumor and/or antiviral activity or natural
products.
Isosteres and isoelectronic analogs of nicotinamide nucleoside (classes 1
and 2) will by synthesized. These C-nucleosides may show potent antitumor
activity by inhibiting IMP-dehydrogenase or they may potentiate the
activity of other anticancer drugs whose mode of action involves DNA strand
disruption.
NAD analogs (class 3) in which the nicotinamide nucleoside is replaced by a
class 1 or class 2 C-nucleoside will be prepared. These analogs may be
more active that the C-nucleosides of classes 1 and 2.
C-Nucleoside analogs (class 4) of the potent antiherpetic and potential
antileukemic agents, FMAU and FEAU, will be synthesized by modification of
a preformed nucleoside (gamma-uridine) at the sugar moiety.
Novel ring transformation reactions will be developed and applied to facile
synthesis of antitumor antibiotics, showdomycin and oxazinomycin, and their
analogs (classes 5 and 6) from Gamma-uridine.
"In house" biochemical and chemotherapeutic collaborative studies for
proper evaluation of the targeted C-nucleosides are described briefly.
From these studies, structure-activity relationships should be forthcoming
to aid in the development of new agents superior to those currently
available for the treatment of cancer and/or viral infection in man.
将发展化学方法来制备六类
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KYOICHI A WATANABE其他文献
KYOICHI A WATANABE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KYOICHI A WATANABE', 18)}}的其他基金
ANTI-POXVIRUS NUCLEOSIDES:SYNTHESIS AND EVALUATION
抗痘病毒核苷:合成与评价
- 批准号:
6555626 - 财政年份:2002
- 资助金额:
$ 16.86万 - 项目类别:
NOVEL NUCLEOSIDES FOR IMAGING DURING CANCER THERAPY
用于癌症治疗期间成像的新型核苷
- 批准号:
2540695 - 财政年份:1997
- 资助金额:
$ 16.86万 - 项目类别:
SYNTHESIS OF ANTITUMOR/VIRAL PYRIMIDINE C-NUCLEOSIDES
抗肿瘤/病毒嘧啶C-核苷的合成
- 批准号:
3171655 - 财政年份:1983
- 资助金额:
$ 16.86万 - 项目类别:
SYNTHESIS OF ANTITUMOR/VIRAL PYRIMIDINE C NUCLEOSIDES
抗肿瘤/病毒嘧啶C核苷的合成
- 批准号:
3171657 - 财政年份:1983
- 资助金额:
$ 16.86万 - 项目类别:
相似海外基金
TOTAL SYNTHESIS OF THE ANTILEUKEMIC AGENT BRYOSTATIN 1
抗白血病剂苔藓抑素 1 的全合成
- 批准号:
3175648 - 财政年份:1984
- 资助金额:
$ 16.86万 - 项目类别:
TOTAL SYNTHESIS OF THE ANTILEUKEMIC AGENT BRYOSTATIN 1
抗白血病剂苔藓抑素 1 的全合成
- 批准号:
3175649 - 财政年份:1984
- 资助金额:
$ 16.86万 - 项目类别:
TOTAL SYNTHESIS OF THE ANTILEUKEMIC AGENT BRYOSTATIN 1
抗白血病剂苔藓抑素 1 的全合成
- 批准号:
3175647 - 财政年份:1984
- 资助金额:
$ 16.86万 - 项目类别:
CYTOTOXIC ACETOGEN FROM ROLLINIA SPECIES; POTENTIAL ANTILEUKEMIC AGENT
来自 Rollinia 物种的细胞毒性产乙酸剂;
- 批准号:
3915346 - 财政年份:
- 资助金额:
$ 16.86万 - 项目类别:














{{item.name}}会员




